STRIDE Biorepository
Purpose
The STRIDE Biorepository is an optional substudy available to participants in "Bone Marrow Transplantation vs Standard of Care in Patients with Severe Sickle Cell Disease (BMT CTN 1503) (STRIDE)".
Condition
- Anemia, Sickle Cell
Eligibility
- Eligible Ages
- Between 15 Years and 40 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Age at least 15 years old to less than 41 years old - Severe sickle cell disease [any clinically significant sickle genotype, for example, Hemoglobin SS (Hb SS), Hemoglobin SC (Hb SC) or Hemoglobin SBeta thalassemia (Hb Sβ), or Hemoglobin S-OArab genotype] with at least 1 of the following manifestations: 1. Clinically significant neurologic event (stroke) or any neurological deficit lasting > 24 hours; 2. History of two or more episodes of acute chest syndrome (ACS) in the 2-year period preceding enrollment despite the institution of supportive care measures (i.e. asthma therapy); 3. An average of three or more pain crises per year in the 2-year period preceding enrollment or referral (required intravenous pain management in the outpatient or inpatient hospital setting); 4. Administration of regular red blood cell (RBC) transfusion therapy, defined as receiving 8 or more transfusions per year(in the 12 months before enrollment to prevent vaso-occlusive clinical complications (i.e. pain, stroke, and acute chest syndrome); 5. An echocardiographic finding of tricuspid valve regurgitant jet (TRJ) velocity ≥ 2.7 m/sec; 6. Ongoing high impact chronic pain on a majority of days per month for at least 6 months. - Adequate physical function as measured by all of the following: 1. Karnofsky/Lansky performance score > or equal to 60 2. Cardiac function: Left ventricular ejection fraction (LVEF) > 40%; or LV shortening fraction > 26% by cardiac echocardiogram or by Multi Gated Acquisition (MUGA) Scan 3. Pulmonary function: Pulse oximetry with a baseline O2 saturation of ≥ 85% and diffusing capacity of the lung for carbon monoxide (DLCO) > 40% (corrected for hemoglobin) 4. Renal function: Serum creatinine ≤ 1.5 x the upper limit of normal for age as per local laboratory and creatinine clearance >70 mL/min; or GFR > 70 mL/min/1.73 m2 by radionuclide Glomerular Filtration Rate (GFR) 5. Hepatic function: Serum conjugated (direct) bilirubin < 2x upper limit of normal for age as per local laboratory; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 5 times upper limit of normal as per local laboratory.
Exclusion Criteria
- Human Leukocyte Antigen (HLA) typing prior to referral (consultation with hematopoietic cell transplantation (HCT) physician). However, if a subject has had HLA typing with accompanying documentation that relatives were not HLA typed and that a search of the unrelated donor registry was not performed the subject will be considered eligible. Documentation will be reviewed and adjudicated by the Protocol Officer or his/her designee. - Uncontrolled bacterial, viral or fungal infection in the 6 weeks before enrollment. - Seropositivity for HIV - Previous HCT or solid organ transplant - Participation in a clinical trial in which the patient received an investigational drug or device must be discontinued at enrollment. - A history of substance abuse as defined by version IV of the Diagnostic & Statistical Manual of Mental Disorders (DSM IV). - Demonstrated lack of compliance with prior medical care (determined by referring physician). - Pregnant or breast feeding females. - Inability to receive HCT due to alloimmunization, defined as the inability to receive packed red blood cell (pRBC) transfusion therapy. Additional Eligibility Criteria for Transplant after Biologic Assignment to the Donor Arm: Participants assigned to the Donor Arm at the time of biologic assignment are subject to additional transplant eligibility criteria as specified below. Additional, repeat clinical assessments prior to transplant should be obtained in accordance with institutional policies and standards of care in the interest of good clinical practice. - Participants must have liver magnetic resonance imaging (MRI) (at least 90 days prior to initiation of transplant conditioning) to document hepatic iron content is required for participants who are currently receiving ≥8 packed red blood cell transfusions for ≥1 year or have received ≥20 packed red blood cell transfusions (cumulative). Participants who have hepatic iron content ≥7 mg Fe/g liver dry weight by liver MRI must have a liver biopsy and histological examination/documentation of the absence of cirrhosis, bridging fibrosis, and active hepatitis (at least 90 days prior to initiation of transplant conditioning). - Cerebral MRI/magnetic resonance angiogram (MRA) within 30 days prior to initiation of transplant conditioning. If there is clinical or radiologic evidence of a recent neurologic event (such as stroke or transient ischemic attack) subjects will be deferred for at least 6 months with repeat cerebral MRI/MRA to ensure stabilization of the neurologic event prior to proceeding to transplantation. - Documentation of participant's willingness to use approved contraception method until discontinuation of all immunosuppressive medications. This is to be documented in the medical record corresponding with the consent conference. - Have a suitably matched HLA donor - Willing and able to donate bone marrow - Absence of anti-donor HLA antibodies
Study Design
- Phase
- Study Type
- Observational [Patient Registry]
- Observational Model
- Cohort
- Time Perspective
- Prospective
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
| Biorepository substudy participants | Participants from the main study who give consent for the genetic testing substudy. |
|
Recruiting Locations
Benioff Children's Hospital at Oakland
Oakland 5378538, California 5332921 94609
Oakland 5378538, California 5332921 94609
Children's National Medical Center
Washington D.C. 4140963, District of Columbia 4138106 20010
Washington D.C. 4140963, District of Columbia 4138106 20010
University of Florida Gainsville
Gainesville 4156404, Florida 4155751 32611
Gainesville 4156404, Florida 4155751 32611
University of Miami
Miami 4164138, Florida 4155751 33136
Miami 4164138, Florida 4155751 33136
Children's Healthcare of Atlanta
Atlanta 4180439, Georgia 4197000 30322
Atlanta 4180439, Georgia 4197000 30322
Emory Children's Center
Atlanta 4180439, Georgia 4197000 30322
Atlanta 4180439, Georgia 4197000 30322
Augusta University Medical Center
Augusta 4180531, Georgia 4197000 30912
Augusta 4180531, Georgia 4197000 30912
University of Chicago
Chicago 4887398, Illinois 4896861 60637
Chicago 4887398, Illinois 4896861 60637
University of Iowa
Iowa City 4862034, Iowa 4862182 52242
Iowa City 4862034, Iowa 4862182 52242
Children's Hospital of New Orleans
New Orleans 4335045, Louisiana 4331987 70118
New Orleans 4335045, Louisiana 4331987 70118
Oschner Medical Center
New Orleans 4335045, Louisiana 4331987 70121
New Orleans 4335045, Louisiana 4331987 70121
University of Michigan Medical Center
Ann Arbor 4984247, Michigan 5001836 48105
Ann Arbor 4984247, Michigan 5001836 48105
Barbara Ann Karmanos Cancer Institute
Detroit 4990729, Michigan 5001836 48201
Detroit 4990729, Michigan 5001836 48201
Washington University/St. Louis Children's Hospital
St Louis 4407066, Missouri 4398678 63110
St Louis 4407066, Missouri 4398678 63110
Hackensack University Medical Center
Hackensack 5098706, New Jersey 5101760 07601
Hackensack 5098706, New Jersey 5101760 07601
Newark Beth Israel Medical Center
Newark 5101798, New Jersey 5101760 07112
Newark 5101798, New Jersey 5101760 07112
New York Presbyterian Brooklyn Methodist Hospital
Brooklyn 5110302, New York 5128638 11215
Brooklyn 5110302, New York 5128638 11215
Icahn School of Medicine at Mount Sinai
New York 5128581, New York 5128638 10029
New York 5128581, New York 5128638 10029
Contact:
John Levine
John Levine
Weill Cornell Medical College
New York 5128581, New York 5128638 10065
New York 5128581, New York 5128638 10065
Montefiore Medical Center/Albert Einstein School of Medicine
The Bronx 5110266, New York 5128638 10467
The Bronx 5110266, New York 5128638 10467
University of North Carolina Hospital at Chapel Hill
Chapel Hill 4460162, North Carolina 4482348 27516
Chapel Hill 4460162, North Carolina 4482348 27516
Duke University Medical Center
Durham 4464368, North Carolina 4482348 27705
Durham 4464368, North Carolina 4482348 27705
Ohio State University
Columbus 4509177, Ohio 5165418 43210
Columbus 4509177, Ohio 5165418 43210
University of Oklahoma
Oklahoma City 4544349, Oklahoma 4544379 73104
Oklahoma City 4544349, Oklahoma 4544379 73104
Children's Hospital of Philadelphia
Philadelphia 4560349, Pennsylvania 6254927 19104
Philadelphia 4560349, Pennsylvania 6254927 19104
Children's Hospital of Pittsburgh
Pittsburgh 5206379, Pennsylvania 6254927 15224
Pittsburgh 5206379, Pennsylvania 6254927 15224
Medical University of South Carolina
Charleston 4574324, South Carolina 4597040 29435
Charleston 4574324, South Carolina 4597040 29435
University of Texas Health Sciences Center
Houston 4699066, Texas 4736286 77004
Houston 4699066, Texas 4736286 77004
Baylor College of Medicine/The Methodist Hospital
Houston 4699066, Texas 4736286 77030
Houston 4699066, Texas 4736286 77030
University of Texas/MD Anderson CRC
Houston 4699066, Texas 4736286 77030
Houston 4699066, Texas 4736286 77030
University of Virginia
Charlottesville 4752031, Virginia 6254928 22908
Charlottesville 4752031, Virginia 6254928 22908
Virginia Commonwealth University
Richmond 4781708, Virginia 6254928 23298
Richmond 4781708, Virginia 6254928 23298
More Details
- NCT ID
- NCT02843347
- Status
- Unknown status
- Sponsor
- Emory University
Detailed Description
A subset of sites for the main study "Bone Marrow Transplantation vs Standard of Care in Patients with Severe Sickle Cell Disease (BMT CTN 1503) (STRIDE)" (NCT02766465) will also participate in the biorepository portion of the study. The purpose of the biorepository is to examine DNA to learn if certain genes predict who will have serious complications of sickle cell disease. The STRIDE Biorepository is an optional substudy available to individuals enrolled in the main study, who are at a participating site. Participants in the main study who consent to take part in the biorepository will have blood drawn at the Baseline Visit. This blood will be shipped to Emory University in Atlanta Georgia and stored for future research.